March #170 : Tomorrow’s Treatments (And Some For Today)

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

For Cryin' Out Loud

Sex and the Salon




Is PrEP Positive?

PEP

We Hear You...And We Know You Hurt.

To a T

The Keys to HIV Nonprogressors

Tomorrow’s Treatments (And Some For Today)




Back From the Brink

Marathon Man

The Melody of HIV

A Tale of Two Tests

Trans Risk

Looking for Love Gloves?

Pozarazzi




Editor's Letter

Letters

Affirmative Ally in Idaho

GMHC Treatment Issues March 2011



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

March 2011


Tomorrow’s Treatments (And Some For Today)

The drug development pipeline currently holds very few new meds to suppress HIV. But on other fronts, drugs to help with side effects and coinfections are here or on their way.

Reduce belly fat
This past November, the FDA approved Egrifta (tesamorelin). Egrifta injections are the first effective treatment for visceral adipose tissue (VAT)—deep belly fat around the liver, stomach and other abdominal organs—a disfiguring, often painful form of lipodystrophy that’s still common among positive people.

Prevent anal cancer
Gardasil, already approved to prevent cervical cancer in girls and young women, and genital warts in young adults and children, now has FDA approval to prevent anal cancer in young people of all sexes, ages 9 to 26. The vaccine targets certain cancer-causing types of human papillomavirus (HPV) and only works in people who haven’t yet acquired those cancer-causing forms of HPV.

Clear hepatitis C
Telaprevir, the first protease inhibitor (PI) for treatment of hepatitis C, awaits FDA approval. The PI has proved effective for people with hard-to-treat hep C genotype 1. In trials, adding telaprevir to standard hep C treatment (pegylated interferon plus ribavirin) shortened treatment time and cleared the virus in people who had previously failed to do so.

Although the original clinical trials did not include people coinfected with HIV, several preliminary studies do, and telaprevir is expected to be effective (and not to interfere with HIV meds) in coinfected people.

Defeat diarrhea
Crofelemer, a compound made from the plant sangre de grado, or dragon’s blood, has shown it can alleviate HIV-related diarrhea. The drug is currently in late-stage clinical trials, and its manufacturer, Napo Pharmaceuticals, could seek approval from the FDA this year.

Search: Egrifta, visceral adipose tissue, coinfections, Gardasil, cervical cancer, genital warts, human papillomavirus, HPV, hepatits C, Telaprevir, plant sangre de grado, diarrhea


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.